Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells

BMC Cancer

Table 1 Wee1 siRNA effects on cell line panel

Cell line	Cancer origin	TP53 status	% viability
A2780	Ovary	WT	98
A549	Lung	WT	102
D54MG	Glioma	WT	93
HCT-116	Colon	WT	74
MCF-7	Breast	WT	65
U87MG	Glioblastoma	WT	42
ZR-75-1	Breast	WT	57
U118MG	Glioblastoma	R213Q	73
HCT-15	Colon	S241F	98
DLD-1	Colon	S241F	89
DAOY	Medulloblastoma	C242F	3
MiaPaca-2	Pancreas	R248W	92
A431	Epidermis	R273H	70
MDA-MB-231	Breast	R280K	15
MDA-MB-453	Breast	368-del30	29
MDA-MB-361	Breast	S166*	5
Calu-6	Lung	R196*	7
HeLa	Cervix	Low (E6)	3
SK-N-MC	Ewing’s	-/-	27
H1299	Lung	-/-	4

Efficacy of Wee1 siRNA treatment was assayed in a panel of 20 solid human cell lines derived from various tumors. Percent viability is measured after five days by taking the average of Wee1 siRNAs #6 and #8 and comparing them to the non-targeting and Ran siRNA controls. p53 genotype data were procured from The p53 Mutation HandBook (http://p53.free.fr[17]). All results are the average of a minimum of three separate experiments.

ISSN: 1471-2407